CN1669573A - 一种治疗心脑血管疾病的中药制剂及其制备方法 - Google Patents
一种治疗心脑血管疾病的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN1669573A CN1669573A CNA2004100187584A CN200410018758A CN1669573A CN 1669573 A CN1669573 A CN 1669573A CN A2004100187584 A CNA2004100187584 A CN A2004100187584A CN 200410018758 A CN200410018758 A CN 200410018758A CN 1669573 A CN1669573 A CN 1669573A
- Authority
- CN
- China
- Prior art keywords
- charge ratio
- ion mass
- fragment ion
- compositions
- glc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 126
- 238000002360 preparation method Methods 0.000 title claims abstract description 110
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 9
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title claims description 12
- 230000008569 process Effects 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 109
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 70
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 70
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 25
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 claims abstract description 24
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 10
- 239000002671 adjuvant Substances 0.000 claims abstract description 8
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 7
- 150000002500 ions Chemical class 0.000 claims description 83
- 239000000203 mixture Substances 0.000 claims description 81
- 239000012634 fragment Substances 0.000 claims description 73
- 239000012071 phase Substances 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 29
- 229930182494 ginsenoside Natural products 0.000 claims description 29
- 229940089161 ginsenoside Drugs 0.000 claims description 29
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 26
- 230000014759 maintenance of location Effects 0.000 claims description 25
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 24
- 239000006187 pill Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 24
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 23
- 229930182490 saponin Natural products 0.000 claims description 23
- 150000007949 saponins Chemical class 0.000 claims description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 18
- KWDWBAISZWOAHD-MHOSXIPRSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]o Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KWDWBAISZWOAHD-MHOSXIPRSA-N 0.000 claims description 17
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 16
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- SOXUSBQFIOBYJU-VPIXDIMLSA-N (2r)-2-[(e)-3-[2-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-1-(3,4-dihydroxyphenyl)-3-oxoprop-1-en-2-yl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C(=C/C=1C=C(O)C(O)=CC=1)C(=O)O[C@H](CC=1C=C(O)C(O)=CC=1)C(O)=O)C1=CC=C(O)C(O)=C1 SOXUSBQFIOBYJU-VPIXDIMLSA-N 0.000 claims description 15
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 15
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 15
- XLXWKULPMYZQSQ-UHFFFAOYSA-N Salvianolic acid E Natural products Cc1ccc(CC(OC(=O)C(=Cc2ccc(O)c(O)c2)c3c(O)c(O)ccc3C=CC(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)C(=O)O)cc1O XLXWKULPMYZQSQ-UHFFFAOYSA-N 0.000 claims description 15
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 15
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 claims description 14
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 13
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 13
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 claims description 13
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 13
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 13
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 13
- UMPZKDHDIZUVTO-UHFFFAOYSA-N Salvianolic acid D Natural products Cc1ccc(C=CC(=O)OC(Cc2ccc(O)c(O)c2)C(=O)O)c(CC(=O)O)c1O UMPZKDHDIZUVTO-UHFFFAOYSA-N 0.000 claims description 13
- KFCMFABBVSIHTB-WUTVXBCWSA-N Salvianolic acid D Chemical compound OC(=O)CC1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C(O)=O)CC1=CC=C(O)C(O)=C1 KFCMFABBVSIHTB-WUTVXBCWSA-N 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 13
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 229960000583 acetic acid Drugs 0.000 claims description 12
- 150000001450 anions Chemical class 0.000 claims description 12
- 239000012567 medical material Substances 0.000 claims description 12
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 11
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 11
- 238000000889 atomisation Methods 0.000 claims description 11
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 11
- KWDWBAISZWOAHD-UHFFFAOYSA-N Ginsenoside Rk1 Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KWDWBAISZWOAHD-UHFFFAOYSA-N 0.000 claims description 10
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 10
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 10
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 10
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 claims description 10
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 claims description 10
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 10
- 239000012362 glacial acetic acid Substances 0.000 claims description 10
- OZTXYFOXQFKYRP-TXRYYSRHSA-N Ginsenoside Rh4 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZTXYFOXQFKYRP-TXRYYSRHSA-N 0.000 claims description 9
- AMPDZVASNOBSQZ-SNVBAGLBSA-N Salvianolic acid G Natural products O=C(O)[C@H]1C(=O)C=2c3c(c(O)ccc3C1)Oc1c(O)c(O)ccc1C=2 AMPDZVASNOBSQZ-SNVBAGLBSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000011010 flushing procedure Methods 0.000 claims description 9
- KFCMFABBVSIHTB-ZZXKWVIFSA-N salvianolic acid g Chemical compound OC(=O)CC1=C(O)C(O)=CC=C1\C=C\C(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 KFCMFABBVSIHTB-ZZXKWVIFSA-N 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 claims description 7
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000010183 spectrum analysis Methods 0.000 claims description 7
- OZTXYFOXQFKYRP-RISAHGKBSA-N Ginsenoside Rh4 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1 OZTXYFOXQFKYRP-RISAHGKBSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 5
- 229930183118 Tanshinone Natural products 0.000 claims description 5
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims description 5
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- -1 arasaponin R2 Chemical compound 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000004531 microgranule Substances 0.000 claims description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229920002545 silicone oil Polymers 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000002826 coolant Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 238000004088 simulation Methods 0.000 abstract 1
- 244000132619 red sage Species 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 19
- 240000007164 Salvia officinalis Species 0.000 description 15
- 235000005412 red sage Nutrition 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 208000031225 myocardial ischemia Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- QOMBXPYXWGTFNR-KRPFXEAISA-N (20E)-Ginsenoside F4 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\C/C=C(\C)/C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QOMBXPYXWGTFNR-KRPFXEAISA-N 0.000 description 3
- AVXFIVJSCUOFNT-QXPABTKOSA-N (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](C(=C)CC/C=C(\C)/C)CC3)C1 AVXFIVJSCUOFNT-QXPABTKOSA-N 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000008899 fufang danshen Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- ZVTVWDXRNMHGNY-JOGTXEPTSA-N Ginsenoside Rg6 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](C(=C)CC/C=C(\C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZVTVWDXRNMHGNY-JOGTXEPTSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000011158 Prunus mume Nutrition 0.000 description 2
- 244000018795 Prunus mume Species 0.000 description 2
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 description 2
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- SVDVJBWDBYSQLO-UHFFFAOYSA-N 5-(4-hydroxy-3-methoxyphenyl)-5-phenylimidazolidine-2,4-dione Chemical compound C1=C(O)C(OC)=CC(C2(C(NC(=O)N2)=O)C=2C=CC=CC=2)=C1 SVDVJBWDBYSQLO-UHFFFAOYSA-N 0.000 description 1
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 1
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
- FNIRVWPHRMMRQI-PGOMJGFXSA-N Notoginsenoside R2 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O FNIRVWPHRMMRQI-PGOMJGFXSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- CVBNMWXECPZOLM-UHFFFAOYSA-N Rhamnetin Natural products COc1cc(O)c2C(=O)C(=C(Oc2c1)c3ccc(O)c(O)c3O)O CVBNMWXECPZOLM-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-KKQCNMDGSA-N beta-D-xylose Chemical compound O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- WQMLFJWIKARBFW-BKKMTDGVSA-N evomonoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(CC[C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)O)[C@]3(C)CC1 WQMLFJWIKARBFW-BKKMTDGVSA-N 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- LLPWNQMSUYAGQI-OOSPGMBYSA-N notoginsenoside R1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LLPWNQMSUYAGQI-OOSPGMBYSA-N 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- LLPWNQMSUYAGQI-UHFFFAOYSA-N notoginsenoside r1 Chemical compound C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)CO3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O LLPWNQMSUYAGQI-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000010365 xinkeshu Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
结构TypeA | 人参皂甙Ginsenoside | R1 | R2 | 分子量MW |
人参皂甙Rb1 | Glc-Glc | Glc-Glc | 1108 | |
人参皂甙Rd | Glc-Glc | Glc | 946 | |
人参皂甙Rg3 | Glc-Glc | H | 784 | |
人参皂甙F2 | Glc | Glc | 784 |
结构TypeB | 人参皂甙Ginsenoside | R1 | R2 | R3 | 分子量MW |
人参皂甙Re | H | Glc | O-Glc-Rham | 946 | |
人参皂甙Rf | H | H | O-Glc-Glc | 800 | |
人参皂甙Rg1 | H | Glc | O-Glc | 800 | |
人参皂甙Rg2 | H | H | O-Glc-Rham | 784 | |
人参皂甙Rh1 | H | H | O-Glc | 638 | |
三七皂甙Notoginsenoside R2 | H | H | O-Glc-Xyl | 770 | |
三七皂甙Notoginsenoside R1 | H | Glc | O-Glc-Xyl | 932 | |
F1 | H | Glc | OH | 638 |
结构TypeC | 人参皂甙Ginsenoside | R1 | R2 | 分子量MW |
人参皂甙Rg5 | Glc-Glc- | H | 766 | |
人参皂甙Rh4 | H | Glc-O- | 620 |
人参皂甙F4 | H | Rham-Glc-O- | 766 |
结构TypeD | 人参皂甙Ginsenoside | R1 | R2 | 分子量MW |
人参皂甙Rg6 | H | Rham-Glc-O- | 766 | |
人参皂甙Rk1 | Glc-Glc | H | 766 | |
人参皂甙Rk3 | H | Glc-O- | 620 |
时间(分钟) | 流动相A(%) | 流动相B(%) | 流动相A:冰乙酸∶水=0.01∶100流动相B:冰乙酸∶乙腈=0.01∶100流速:0.5毫升/分钟温度:30℃检测波长:多波长检测(显示波长280nm) |
0 | 95 | 5 | |
15 | 78.3 | 21.7 | |
33 | 78.3 | 21.7 | |
38 | 65 | 35 |
HPLC-MS | HPLC-MSn | |
离子检测方式 | 负离子检测 | |
干燥气流速Dry gas flow rate(L/min) | 10 | 10 |
雾化气压力Nebulizerpressure(psi) | 60 | 60 |
干燥气温度Dry temp.(℃) | 350 | 350 |
毛细管压力Capillary voltage(v) | 3500 | 3500 |
质量扫描范围Mass scan range(m/z) | 100-1200 | 100-800 |
碰撞断裂振幅Fragment ampl. | 1.5-3.0 |
时间(分钟) | 流动相A(%) | 流动相B(%) | 流动相A:冰乙酸∶水=0.01∶100流动相B:冰乙酸∶乙腈=0.01∶100流速:0.8毫升/分钟温度:30℃检测波长:多波长检测(显示波长203nm) |
0 | 80 | 20 | |
15 | 65 | 35 | |
25 | 65 | 35 | |
40 | 57 | 43 | |
50 | 54 | 46 | |
65 | 42 | 58 | |
75 | 25 | 75 |
HPLC-MS | HPLC-MSn |
离子检测方式 | 负离子检测 | |
Dry gas flow rate(L/min) | 10 | 10 |
Nebulizer pressure(psi) | 60 | 60 |
Dry temp.(℃) | 350 | 350 |
Capillary voltage(v) | 3500 | 3500 |
Mass scan range(m/z) | 400-1500 | 400-1200 |
Fragment ampl. | 1.2-1.5 |
峰号Peak No. | 保留时间Ret Time | 准分子离子质峰质荷比[M-H] | 成分Identity | 最大吸收波长λmax |
1 | 12.73 | 197 | 丹参素(Danshensu) | 280 |
2 | 19.69 | 137 | 原儿茶醛(Protocatechualdehyde) | 231,280,310 |
3 | 22.99 | 537 | 异紫草酸A(Isolithospermic acid) | 327 |
4 | 23.83 | 537 | 异紫草酸B(Isolithospermic acid) | 327 |
5 | 24.89 | 417 | 丹酚酸D(Salvianolic acid D) | 247,321 |
6 | 26.7 | 717 | 丹酚酸E(Salvianolic acid E) | 330 |
7 | 28.51 | 359 | 迷迭香酸(Rosmarinic acid) | 329 |
8 | 31.93 | 717 | 丹酚酸B(Salvianolic acid B) | 254,286,309 |
9 | 34.86 | 339 | 丹酚酸G(Salvianolic acid G) | 395 |
10 | 44.64 | 493 | 丹酚酸A(Salvianolic acid A) | 288 |
峰号PeakNo. | 成分Identity | 碎片离子质荷比Fragment ion m/z |
3 | 异紫草酸A | 二级(537):493[M-H-CO2]-,295[M-CO2-R-H2O]三级(295):159,109 |
4 | 异紫草酸B | 二级(537):493[M-H-CO2]-,295[M-CO2-R-H2O]三级(295):159,109 |
5 | 丹酚酸D | 二级(417):175[M-CO2-R-H2O],373[M-H-CO2]-三级(175):147,157,133 |
6 | 丹酚酸E | 二级(717):519[M-R-H2O],321[M-2R-2H2O]三级(519):321[M-R-H2O],339[M-R]三级(321):279,293,249,223,185 |
7 | 迷迭香酸 | 二级(359):161[M-R-H2O],179[M-R],195 |
8 | 丹酚酸B | 二级(717):519[M-R-H2O],321[M-2R-2H2O]三级(519):321[M-R-H2O],339[M-R]四级(321):279,293,249,233,185 |
9 | 丹酚酸G | 二级(339):321[M-H-H2O],295[M-H-CO2]三级(295):279,267四级(279):251 |
10 | 丹酚酸A | 二级(493):295[M-R-H2O]三级(295):159,109 |
峰号Peak No. | 保留时间Ret Time | 准分子离子质峰质荷比m/z | 成分Identity |
1 | 24.36 | 277[M+H]+,575[2M+Na]+ | 丹参酮I |
2 | 34.85 | 295[M+H]+,611[2M+Na]+ | 丹参酮IIA |
峰号Peak No. | 保留时间RetTime | 保留时间Ret Time | 准分子离子质峰质荷比[M-H] | 成分Identity |
1 | 11.27 | 10.68 | 931 | 三七皂苷R1 |
2 | 12.38 | 12.38 | 945 | 人参皂苷Re |
2 | 12.53 | 12.5 | 799 | 人参皂苷Rg1 |
3 | 20.81 | 21.95 | 1107 | 人参皂苷Rb1 |
4 | 21.25 | 22.52 | 769 | 三七皂苷R2 |
5 | 22.53 | 23.8 | 769 | 三七皂苷R2 iso. |
6 | 22.85 | 24.07 | 783 | 人参皂苷Rg2 |
7 | 23.77 | 25.02 | 637 | 人参皂苷Rh1 |
8 | 25 | 26.25 | 637 | 人参皂苷Rh1 iso.(F1) |
9 | 30.05 | 31.05 | 945 | 人参皂苷Rd |
10 | 34.81 | 35.8 | 945 | 人参皂苷Rd iso. |
11 | 40.00 | 40.77 | 781 | 人参皂苷Rf-H2O |
12 | 41.57 | 42.04 | 751 | 三七皂苷R2-H2O |
13 | 43.72 | 43.72 | 751 | 三七皂苷R2-H2O |
14 | 44.89 | 44.89 | 765 | 人参皂苷Rg6/F4 |
15 | 46.43 | 46.43 | 619 | 人参皂苷Rk3/Rh4(Rk3) |
16 | 48.68 | 48.68 | 619 | 人参皂苷Rk3/Rh4(Rh4) |
17 | 54.97 | 54.97 | 783 | 人参皂苷20(R)Rg3 |
18 | 56.48 | 56.48 | 783 | 人参皂苷20(S)Rg3 |
19 | 68.35 | 68.35 | 765 | 人参皂苷Rk1/Rg5(Rk1) |
20 | 69.53 | 69.53 | 765 | 人参皂苷Rk1/Rg5(Rg5) |
保留时间Ret Time | 成分Identity | 准分子离子质峰质荷比m/z |
11.27 | 三七皂苷R1 | 799[M-H-Xyl];637[M-H-Xyl-Glc];475[M-H-Xyl-2Glc] |
12.38 | 人参皂苷Re | 799[M-H-Rham];783[M-H-Glc];637[M-H-Rham-Glc];475[M-H-Rham-2Glc] |
12.53 | 人参皂苷Rg1 | 637[M-H-Glc];475[M-H-2Glc] |
20.81 | 人参皂苷Rb1 | 945[M-H-Glc];783[M-H-2Glc];621[M-H-3Glc];459[M-H-4Glc] |
21.25 | 三七皂苷R2 | 637[M-H-Xyl];475[M-H-Xyl-Glc] |
22.53 | 三七皂苷R2 iso. | 637[M-H-Xyl];475[M-H-Xyl-Glc] |
22.85 | 人参皂苷Rg2 | 637[M-H-Rham];475[M-H-Rham-Glc] |
23.77 | 人参皂苷Rh1 | 475[M-H-Glc] |
25 | 人参皂苷Rh1 iso.(F1) | 475[M-H-Glc] |
30.05 | 人参皂苷Rd | 783[M-H-Glc];621[M-H-2Glc];459[M-H-3Glc] |
34.81 | 人参皂苷Rd iso. | 783[M-H-Glc];621[M-H-2Glc];459[M-H-3Glc] |
40.00 | 人参皂苷Rf-H2O | 619[M-H-Glc];457[M-H-2Glc] |
41.57 | 三七皂苷R2-H2O | 619[M-H-Xyl] |
43.72 | 三七皂苷R2-H2O | 619[M-H-Xyl] |
44.89 | 人参皂苷Rg6/F4 | 619[M-H-Rham];457[M-H-Rham-Glc] |
54.97 | 人参皂苷20(R)Rg3 | 621[M-H-Glc];459[M-H-2Glc] |
56.48 | 人参皂苷20(S)Rg3 | 621[M-H-Glc];459[M-H-2Glc] |
68.35 | 人参皂苷Rk1/Rg5(Rk1) | 603[M-H-Glc];441[M-H-2Glc] |
69.53 | 人参皂苷Rk1/Rg5(Rg5) | 603[M-H-Glc];441[M-H-2Glc] |
Time | A:0.01%HAC-H2O(%) | B:0.01%HAC-CH3CN(%) |
0152540506575 | 80656557574225 | 20353543435875 |
峰号 | 平均保留时间 | 保留时间RSD% | 平均峰面积 | 峰面积RSD% | 单峰占总峰面积的百分比 | 单峰占总峰面积的百分比范围 |
1 | 10.87 | 0.45 | 506.92 | 13.03 | 4.27% | 3.7%-4.8% |
2 | 12.12 | 0.34 | 2723.73 | 12.11 | 22.93% | 20.2%-25.7% |
3 | 20.34 | 0.23 | 1684.49 | 18.95 | 14.18% | 11.5%-16.9% |
4 | 20.86 | 0.16 | 231.84 | 18.99 | 1.95% | 1.6%-2.3% |
5 | 23.29 | 0.25 | 565.78 | 13.8 | 4.76% | 4.1%-5.4% |
6 | 24.48 | 0.28 | 309.39 | 18.98 | 2.60% | 2.1%-3.1% |
7 | 29 | 0.62 | 345.32 | 14.28 | 2.91% | 2.5%-3.3% |
8 | 41.21 | 0.25 | 436.06 | 10.88 | 3.67% | 3.3%-4.1% |
9 | 42.94 | 0.21 | 665.38 | 11.82 | 5.60% | 4.9%-6.3% |
10 | 44.16 | 0.21 | 472.84 | 14.59 | 3.98% | 3.4%-4.6% |
11 | 45.68 | 0.23 | 947.39 | 16.06 | 7.97% | 6.7%-9.3% |
12 | 47.88 | 0.25 | 1547.8 | 13.25 | 13.03% | 11.3%-14.8% |
13 | 68.21 | 0.13 | 622.91 | 10.39 | 5.24% | 4.7%-5.8% |
14 | 69.43 | 0.12 | 820.24 | 12.93 | 6.90% | 6.0%-7.8% |
保留时间 | 流动相A | 流动相A |
0min8min15min55min | 90%(v/v)78%74%48% | 10%22%26%52% |
峰号 | 平均保留时间 | 保留时间RSD% | 平均峰面积 | 峰面积RSD% | 单峰占总峰面积的百分比 | 单峰占总峰面积的百分比范围 |
1 | 6.04 | 0.31 | 1627.92 | 5.91 | 20.80% | 19.6%-22.0% |
2 | 9.9 | 0.25 | 2575.54 | 13.53 | 32.90% | 28.5%-37.4% |
3 | 16.89 | 0.61 | 366.89 | 10.92 | 4.69% | 4.2%-5.2% |
4 | 17.84 | 0.7 | 381.4 | 13.81 | 4.87% | 4.2%-5.5% |
5 | 20.31 | 0.96 | 186.08 | 12.04 | 2.38% | 2.1%-2.7% |
6 | 23.74 | 0.76 | 555.35 | 10.48 | 7.09% | 6.4%-7.8% |
7 | 27.73 | 0.5 | 281.91 | 18.08 | 3.60% | 3.0%-4.3% |
8 | 31.02 | 1.18 | 1852.33 | 14.84 | 23.66% | 20.2%-27.2% |
Claims (15)
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100187584A CN100450501C (zh) | 2004-03-17 | 2004-03-17 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
JP2007503177A JP5567763B2 (ja) | 2004-03-17 | 2005-03-17 | 心臓−脳血管の疾病に対する伝統的中国医学の調合剤およびその製造方法 |
PT57291098T PT1741439T (pt) | 2004-03-17 | 2005-03-17 | Preparação de medicina chinesa tradicional para doenças dos vasos sanguíneos cardiocerebrais e seu método de preparação |
ES05729109.8T ES2635869T3 (es) | 2004-03-17 | 2005-03-17 | Preparación de medicina tradicional china para enfermedades de vasos sanguíneos cardio-cerebrales y su método de preparación |
HUE05729109A HUE036016T2 (hu) | 2004-03-17 | 2005-03-17 | Tradicionális kínai gyógyszerkészítmény cardio-cerebrális véredény betegségek számára és elõállítási eljárása |
MXPA06010597A MXPA06010597A (es) | 2004-03-17 | 2005-03-17 | Preparacion de medicina tradicional. |
NZ550335A NZ550335A (en) | 2004-03-17 | 2005-03-17 | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
UAA200610937A UA88162C2 (ru) | 2004-03-17 | 2005-03-17 | ПРЕПАРАТ ТРАДИЦИОННОЙ КИТАЙСКОЙ МЕДИЦИНЫ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ НА ОСНОВЕ ЭКСТРАКТОВ Salviae Miltiorrhizae И Radix Notoginseng И СПОСОБ ЕГО ПОЛУЧЕНИЯ |
AP2006003788A AP2644A (en) | 2004-03-17 | 2005-03-17 | Traditional chinese medicine preparation for cardiocerebral blood vessel diseases and its preparing method |
AU2005221260A AU2005221260B2 (en) | 2004-03-17 | 2005-03-17 | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
KR1020067021522A KR20070027532A (ko) | 2004-03-17 | 2005-03-17 | 심장-뇌 혈관성 질환용 한약 조제물 및 그의 제조 방법 |
EP05729109.8A EP1741439B1 (en) | 2004-03-17 | 2005-03-17 | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
PCT/CN2005/000333 WO2005087242A1 (en) | 2004-03-17 | 2005-03-17 | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
RU2006136529/15A RU2359692C2 (ru) | 2004-03-17 | 2005-03-17 | Лекарственный препарат для лечения заболеваний кардиоцеребральных кровеносных сосудов и способ его изготовления |
DK05729109.8T DK1741439T3 (en) | 2004-03-17 | 2005-03-17 | TRADITIONAL CHINESE MEDICINE PREPARATION AGAINST CARDIO-CEREBRAL BLOOD CARE DISEASES AND METHOD OF PRODUCING THEREOF |
CA2559826A CA2559826C (en) | 2004-03-17 | 2005-03-17 | Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
PL05729109T PL1741439T3 (pl) | 2004-03-17 | 2005-03-17 | Preparat tradycyjnej medycyny chińskiej na choroby naczyń krwionośnych sercowo-mózgowych i sposób jego otrzymywania |
LTEP05729109.8T LT1741439T (lt) | 2004-03-17 | 2005-03-17 | Tradicinis kiniečių vaistinis preparatas, skirtas gydyti širdies-smegenų kraujagyslių ligas, ir jo gavimo būdas |
US11/522,296 US7396545B2 (en) | 2004-03-17 | 2006-09-15 | Preparation for cardio-cerebral blood vessel diseases and its preparing method |
NO20064572A NO345093B1 (no) | 2004-03-17 | 2006-10-10 | Medisinsk preparat basert på ekstrakter av Radix Salviae Miltiorrhizae og Radix Notoginseng for anvendelse i behandling av kardiovaskulære- og cerebrovaskulære sykdommer, fremgangsmåte for framstilling derav og anvendelse derav |
ZA200608606A ZA200608606B (en) | 2004-03-17 | 2006-10-16 | Traditional Chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100187584A CN100450501C (zh) | 2004-03-17 | 2004-03-17 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1669573A true CN1669573A (zh) | 2005-09-21 |
CN100450501C CN100450501C (zh) | 2009-01-14 |
Family
ID=34975326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100187584A Expired - Lifetime CN100450501C (zh) | 2004-03-17 | 2004-03-17 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7396545B2 (zh) |
EP (1) | EP1741439B1 (zh) |
JP (1) | JP5567763B2 (zh) |
KR (1) | KR20070027532A (zh) |
CN (1) | CN100450501C (zh) |
AP (1) | AP2644A (zh) |
AU (1) | AU2005221260B2 (zh) |
CA (1) | CA2559826C (zh) |
DK (1) | DK1741439T3 (zh) |
ES (1) | ES2635869T3 (zh) |
HU (1) | HUE036016T2 (zh) |
LT (1) | LT1741439T (zh) |
MX (1) | MXPA06010597A (zh) |
NO (1) | NO345093B1 (zh) |
NZ (1) | NZ550335A (zh) |
PL (1) | PL1741439T3 (zh) |
PT (1) | PT1741439T (zh) |
RU (1) | RU2359692C2 (zh) |
UA (1) | UA88162C2 (zh) |
WO (1) | WO2005087242A1 (zh) |
ZA (1) | ZA200608606B (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100360931C (zh) * | 2005-11-02 | 2008-01-09 | 中国药科大学 | 一种丹参和三七制剂的质量控制方法 |
CN100392400C (zh) * | 2005-11-01 | 2008-06-04 | 上海中医药大学 | 生物体液中丹酚酸b浓度测定样品的预处理方法 |
WO2008131648A1 (fr) * | 2007-04-27 | 2008-11-06 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd. | Détection de danshensu de plasma sanguin et d'acide salvianolique b d'un extrait de plante éliminant l'hémostase |
CN101244104B (zh) * | 2008-03-24 | 2011-05-25 | 中国科学院长春应用化学研究所 | 一种增加人参总皂苷提取物中稀有皂苷含量的方法 |
US7989212B2 (en) | 2007-04-27 | 2011-08-02 | Shanghai Sundise | Detection of blood plasma schizadrin B of dissipating blood stasis botanical |
US8334110B2 (en) | 2007-04-27 | 2012-12-18 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd. | Detection of blood plasma amygdalin of dissipating blood stasis botanical |
CN103235050A (zh) * | 2013-04-12 | 2013-08-07 | 黑龙江珍宝岛药业股份有限公司 | 三七总皂苷注射剂的质量控制方法 |
CN103424476A (zh) * | 2012-05-25 | 2013-12-04 | 天津天士力之骄药业有限公司 | 同时测定丹参多酚酸中4种水溶性成分的方法 |
WO2015003659A1 (zh) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | 一种中药组合物及其制剂和用途 |
WO2015003662A1 (zh) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | 一种中药组合物及其制剂和用途 |
WO2015027891A1 (zh) * | 2013-08-29 | 2015-03-05 | 天士力制药集团股份有限公司 | 一种新的丹酚酸化合物t、其制备方法和用途 |
US9161959B2 (en) | 2007-04-29 | 2015-10-20 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd | Use of a vegetable drug composition in the manufacturing of pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis |
CN109633009A (zh) * | 2018-12-28 | 2019-04-16 | 广西中医药大学 | 一种丹参及其提取物的质量控制方法 |
CN110907581A (zh) * | 2019-12-23 | 2020-03-24 | 广州医药研究总院有限公司 | 复方丹参制剂七种成分血浆或组织浓度的质谱检测方法 |
US11013694B2 (en) | 2013-07-11 | 2021-05-25 | Tasly Pharmaceutical Group Co., Ltd. | Formulation of a micro drop pill and the preparation method thereof |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8486464B2 (en) * | 2000-12-22 | 2013-07-16 | Tasly Pharmaceutical Group Co. Ltd. | Herbal composition for angina pectoris, method to prepare same and uses thereof |
US20050037094A1 (en) * | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
CN100392399C (zh) * | 2005-12-28 | 2008-06-04 | 劲牌有限公司 | 用指纹图谱技术检测中国劲酒质量的方法 |
CN101524352A (zh) | 2008-03-04 | 2009-09-09 | 江苏先声药物研究有限公司 | 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物 |
US20120041062A1 (en) * | 2009-03-30 | 2012-02-16 | Tianjin Tasly Pharmaceutical Co., Ltd. | Compound of salvianolic acid l, preparation method and use thereof |
CN102100739B (zh) * | 2009-12-17 | 2013-12-25 | 天士力制药集团股份有限公司 | 一种含有丹参素和三七皂苷r1的中药组合物及其应用 |
CN102293821A (zh) * | 2010-06-28 | 2011-12-28 | 天津天士力制药股份有限公司 | 一种中药组合物在制备减轻急性心肌梗死后心绞痛发作的药物中的应用 |
ES2624285T3 (es) * | 2010-08-06 | 2017-07-13 | Tasly Pharmaceutical Group Co., Ltd. | Uso de una composición de Salvia miltiorrhiza en la preparación de fármacos para la prevención secundaria de una enfermedad cardíaca coronaria |
KR101445303B1 (ko) * | 2011-06-30 | 2014-09-26 | 한국생명공학연구원 | 가공인삼의 원산지 또는 연령 판별용 표준 마커, 이의 확립방법 또는 이를 이용한 원산지 또는 연령 판별방법 |
CN102680626A (zh) * | 2012-05-09 | 2012-09-19 | 正大青春宝药业有限公司 | 一种参麦注射液中特征性成分的定量检测方法 |
CA2878071A1 (en) * | 2012-07-05 | 2014-01-09 | Eden Shield Ltd. | Novel pest repellents from plant extracts |
KR101980183B1 (ko) | 2013-03-01 | 2019-05-20 | 키무시코라이닌징 가부시키가이샤 | 진세노사이드 조성물 |
CN103245687B (zh) * | 2013-05-07 | 2017-10-13 | 江苏省中医药研究院 | 一种丹参注射液的基于组分结构的质量控制检测方法 |
JP6372897B2 (ja) * | 2013-08-29 | 2018-08-15 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | 漢方薬組成物 |
RU2539133C1 (ru) * | 2013-10-09 | 2015-01-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" | Иммунокорректирующее средство для терапии атеросклеротических заболеваний |
KR101409848B1 (ko) * | 2014-03-03 | 2014-06-19 | 한국생명공학연구원 | 가공인삼의 원산지 또는 연령 판별용 표준 마커, 이의 확립방법 또는 이를 이용한 원산지 또는 연령 판별방법 |
TWI535784B (zh) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | 剪切增稠配方、及包含其之複合材料 |
CN104374844A (zh) * | 2014-11-13 | 2015-02-25 | 贵州信邦制药股份有限公司 | 丹参药材中水溶性成分的含量测定方法及其应用 |
CN104749280A (zh) * | 2015-03-30 | 2015-07-01 | 神威药业集团有限公司 | 一种丹参注射液的质量控制方法 |
CN104749308A (zh) * | 2015-03-30 | 2015-07-01 | 神威药业集团有限公司 | 一种丹参注射液的质量控制方法 |
CN106290677B (zh) * | 2016-09-29 | 2018-01-02 | 国药集团冯了性(佛山)药业有限公司 | 冯了性风湿跌打药酒指纹图谱的建立方法及其指纹图谱 |
CN107315061B (zh) * | 2017-06-15 | 2019-01-25 | 甘肃兰药药业有限公司 | 一种治疗妇女子宫出血的茜芷中药制剂的检测方法 |
CN110156863B (zh) * | 2018-02-12 | 2022-12-13 | 吉林紫鑫参工堂生物科技有限公司 | 一种人参皂苷Rd自动控制分离纯化方法 |
CN109115904B (zh) * | 2018-07-25 | 2021-02-02 | 山西广誉远国药有限公司 | 一种定坤丹uplc指纹图谱的构建方法及其应用 |
CN111289648B (zh) * | 2020-03-09 | 2021-12-17 | 四川省中医药科学院 | 一种中药复方制剂指纹图谱的建立方法及其指纹图谱 |
CN112843041A (zh) * | 2021-01-08 | 2021-05-28 | 中国人民解放军空军军医大学 | 迷迭香酸或其衍生物作为新型trpc1拮抗剂的药用制备及其应用 |
CN113004364A (zh) * | 2021-03-25 | 2021-06-22 | 杭州天草科技有限公司 | 一种高纯度人参皂苷Re的制备方法 |
CN113820405A (zh) * | 2021-08-10 | 2021-12-21 | 劲牌有限公司 | 一种石韦配方颗粒质量控制方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1072012C (zh) * | 1999-06-30 | 2001-10-03 | 韩桂茹 | 丹参中丹参素及原儿茶醛的提取工艺 |
BRPI0116589B1 (pt) * | 2000-12-22 | 2018-07-03 | Tasly Pharmaceutical Group Co., Ltd. | Composição herbal para angina pectoris, método para prepará-la e uso desta |
US8486464B2 (en) * | 2000-12-22 | 2013-07-16 | Tasly Pharmaceutical Group Co. Ltd. | Herbal composition for angina pectoris, method to prepare same and uses thereof |
FR2822701B1 (fr) * | 2001-04-03 | 2005-03-18 | Lvmh Rech | Utilisation d'un extrait d'algue phaeodactylum comme agent cosmetique favorisant l'activite du proteasome des cellules de la peau et composition cosmetique le contenant |
WO2002085398A1 (en) * | 2001-04-19 | 2002-10-31 | Taipei-Veterans General Hospital | Lithospermic acid-containing composition |
US6703053B2 (en) * | 2001-10-24 | 2004-03-09 | Tampa Bay Research Institute | Anti-HSV agent for inhibiting replication of HSV-1 and HSV-2 and method of producing a substance having anti-HSV activity |
JP3987733B2 (ja) * | 2002-02-12 | 2007-10-10 | 共栄化学工業株式会社 | 線維芽細胞賦活剤及びこれを含む皮膚外用剤 |
CN1470255A (zh) * | 2002-07-22 | 2004-01-28 | 王智民 | 自丹参三七中提取的制备物及其复方制备方法和医疗用途 |
CN100421683C (zh) * | 2002-12-31 | 2008-10-01 | 北京采瑞医药有限公司 | 一种治疗心脑血管疾病的复方丹参微囊制剂及其制备方法 |
US20050037094A1 (en) * | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
-
2004
- 2004-03-17 CN CNB2004100187584A patent/CN100450501C/zh not_active Expired - Lifetime
-
2005
- 2005-03-17 AP AP2006003788A patent/AP2644A/xx active
- 2005-03-17 CA CA2559826A patent/CA2559826C/en active Active
- 2005-03-17 RU RU2006136529/15A patent/RU2359692C2/ru active
- 2005-03-17 WO PCT/CN2005/000333 patent/WO2005087242A1/zh active Application Filing
- 2005-03-17 JP JP2007503177A patent/JP5567763B2/ja active Active
- 2005-03-17 DK DK05729109.8T patent/DK1741439T3/en active
- 2005-03-17 ES ES05729109.8T patent/ES2635869T3/es active Active
- 2005-03-17 EP EP05729109.8A patent/EP1741439B1/en active Active
- 2005-03-17 UA UAA200610937A patent/UA88162C2/ru unknown
- 2005-03-17 AU AU2005221260A patent/AU2005221260B2/en active Active
- 2005-03-17 KR KR1020067021522A patent/KR20070027532A/ko not_active Application Discontinuation
- 2005-03-17 PL PL05729109T patent/PL1741439T3/pl unknown
- 2005-03-17 LT LTEP05729109.8T patent/LT1741439T/lt unknown
- 2005-03-17 PT PT57291098T patent/PT1741439T/pt unknown
- 2005-03-17 MX MXPA06010597A patent/MXPA06010597A/es active IP Right Grant
- 2005-03-17 NZ NZ550335A patent/NZ550335A/en unknown
- 2005-03-17 HU HUE05729109A patent/HUE036016T2/hu unknown
-
2006
- 2006-09-15 US US11/522,296 patent/US7396545B2/en active Active
- 2006-10-10 NO NO20064572A patent/NO345093B1/no unknown
- 2006-10-16 ZA ZA200608606A patent/ZA200608606B/en unknown
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100392400C (zh) * | 2005-11-01 | 2008-06-04 | 上海中医药大学 | 生物体液中丹酚酸b浓度测定样品的预处理方法 |
CN100360931C (zh) * | 2005-11-02 | 2008-01-09 | 中国药科大学 | 一种丹参和三七制剂的质量控制方法 |
WO2008131648A1 (fr) * | 2007-04-27 | 2008-11-06 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd. | Détection de danshensu de plasma sanguin et d'acide salvianolique b d'un extrait de plante éliminant l'hémostase |
US7989212B2 (en) | 2007-04-27 | 2011-08-02 | Shanghai Sundise | Detection of blood plasma schizadrin B of dissipating blood stasis botanical |
US7993928B2 (en) | 2007-04-27 | 2011-08-09 | Shanghai Sundise | Detection of blood plasma Danshensu and Salvianolic acid B dissipating blood stasis botanical |
US8334110B2 (en) | 2007-04-27 | 2012-12-18 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd. | Detection of blood plasma amygdalin of dissipating blood stasis botanical |
US9161959B2 (en) | 2007-04-29 | 2015-10-20 | Shanghai Sundise Chinese Medicine Technology Development Co., Ltd | Use of a vegetable drug composition in the manufacturing of pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis |
CN101244104B (zh) * | 2008-03-24 | 2011-05-25 | 中国科学院长春应用化学研究所 | 一种增加人参总皂苷提取物中稀有皂苷含量的方法 |
CN103424476A (zh) * | 2012-05-25 | 2013-12-04 | 天津天士力之骄药业有限公司 | 同时测定丹参多酚酸中4种水溶性成分的方法 |
CN103424476B (zh) * | 2012-05-25 | 2016-08-17 | 天津天士力之骄药业有限公司 | 同时测定丹参多酚酸中4种水溶性成分的方法 |
CN103235050A (zh) * | 2013-04-12 | 2013-08-07 | 黑龙江珍宝岛药业股份有限公司 | 三七总皂苷注射剂的质量控制方法 |
CN103235050B (zh) * | 2013-04-12 | 2014-12-03 | 黑龙江珍宝岛药业股份有限公司 | 一种三七总皂苷注射剂的液相色谱检测方法 |
US11013694B2 (en) | 2013-07-11 | 2021-05-25 | Tasly Pharmaceutical Group Co., Ltd. | Formulation of a micro drop pill and the preparation method thereof |
USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
WO2015003659A1 (zh) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | 一种中药组合物及其制剂和用途 |
TWI621443B (zh) * | 2013-07-11 | 2018-04-21 | Tasly Pharmaceutical Group Co Ltd | 中藥組合物及其用途、包含該中藥組合物之藥物製劑及複方丹參微滴丸劑、及該微滴丸劑的製備方法 |
US9987320B2 (en) | 2013-07-11 | 2018-06-05 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
US9999630B2 (en) | 2013-07-11 | 2018-06-19 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
TWI631956B (zh) * | 2013-07-11 | 2018-08-11 | 大陸商天士力醫藥集團股份有限公司 | 中藥組合物及其用途、包含該中藥組合物之藥物製劑及複方丹參微滴丸劑、及該微滴丸劑的製備方法 |
WO2015003662A1 (zh) * | 2013-07-11 | 2015-01-15 | 天士力制药集团股份有限公司 | 一种中药组合物及其制剂和用途 |
AU2014289766B2 (en) * | 2013-07-11 | 2019-03-14 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
USRE49035E1 (en) | 2013-07-11 | 2022-04-19 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
EA034217B1 (ru) * | 2013-07-11 | 2020-01-17 | Тасли Фармасьютикал Груп Ко., Лтд. | Композиция традиционной китайской медицины, фармацевтический препарат и капельная микропилюля из нее, способ получения капельной микропилюли и применение композиции |
RU2668955C2 (ru) * | 2013-08-29 | 2018-10-05 | Тасли Фармасьютикал Груп Ко., Лтд. | Новое соединение сальвианоловой кислоты т, способ его получения и его применение |
US10626077B2 (en) | 2013-08-29 | 2020-04-21 | Tasly Pharmaceutical Group Co., Ltd. | Salvianolic acid compound T, preparation method therefor, and use thereof |
WO2015027891A1 (zh) * | 2013-08-29 | 2015-03-05 | 天士力制药集团股份有限公司 | 一种新的丹酚酸化合物t、其制备方法和用途 |
CN109633009A (zh) * | 2018-12-28 | 2019-04-16 | 广西中医药大学 | 一种丹参及其提取物的质量控制方法 |
CN110907581A (zh) * | 2019-12-23 | 2020-03-24 | 广州医药研究总院有限公司 | 复方丹参制剂七种成分血浆或组织浓度的质谱检测方法 |
CN110907581B (zh) * | 2019-12-23 | 2022-07-01 | 广州医药研究总院有限公司 | 复方丹参制剂七种成分血浆或组织浓度的质谱检测方法 |
Also Published As
Publication number | Publication date |
---|---|
ES2635869T3 (es) | 2017-10-05 |
CA2559826A1 (en) | 2005-09-22 |
UA88162C2 (ru) | 2009-09-25 |
ZA200608606B (en) | 2008-06-25 |
WO2005087242A1 (en) | 2005-09-22 |
RU2359692C2 (ru) | 2009-06-27 |
JP5567763B2 (ja) | 2014-08-06 |
JP2007529431A (ja) | 2007-10-25 |
HUE036016T2 (hu) | 2018-06-28 |
NO345093B1 (no) | 2020-09-28 |
RU2006136529A (ru) | 2008-04-27 |
AU2005221260A1 (en) | 2005-09-22 |
AP2006003788A0 (en) | 2006-10-31 |
PL1741439T3 (pl) | 2017-10-31 |
CA2559826C (en) | 2015-10-06 |
KR20070027532A (ko) | 2007-03-09 |
PT1741439T (pt) | 2017-08-23 |
CN100450501C (zh) | 2009-01-14 |
DK1741439T3 (en) | 2017-08-07 |
EP1741439B1 (en) | 2017-05-31 |
LT1741439T (lt) | 2017-08-25 |
US7396545B2 (en) | 2008-07-08 |
MXPA06010597A (es) | 2007-03-15 |
AU2005221260B2 (en) | 2010-02-11 |
AP2644A (en) | 2013-04-17 |
US20070071834A1 (en) | 2007-03-29 |
EP1741439A4 (en) | 2009-08-12 |
EP1741439A1 (en) | 2007-01-10 |
NO20064572L (no) | 2006-12-18 |
NZ550335A (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1669573A (zh) | 一种治疗心脑血管疾病的中药制剂及其制备方法 | |
CN1754541A (zh) | 甾体皂苷药物组合物及其制备方法和用途 | |
CN1419124A (zh) | 一种治疗心脑血管疾病的复方丹参制剂的质量控制方法 | |
CN1872199A (zh) | 一种中药组合物及其制备方法 | |
CN1267111C (zh) | 一种治疗心脑血管疾病的复方丹参滴丸及其制备方法 | |
CN1186051C (zh) | 一种化痰止咳的药物及其生产方法 | |
CN1296063C (zh) | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 | |
CN1943569A (zh) | 一种中药活性成分组合物及其制备方法和用途 | |
CN111920799B (zh) | 一种苦乐果有效成分组合物及其制备方法和应用 | |
CN1582952A (zh) | 积雪草总苷在制备防治心、脑血管疾病药物中的用途 | |
CN1257710C (zh) | 一种丹参药材中有效部位的制剂及其制备方法 | |
CN1679870A (zh) | 复方丹参滴丸质量控制方法 | |
CN1319550C (zh) | 用于治疗心血管疾病的中药制剂及其制备方法和质量控制方法 | |
CN1670524A (zh) | 一种复方丹参滴丸指纹图谱的测定方法 | |
CN1891256A (zh) | 一种冠心丹参分散片及其制备方法 | |
CN1891266A (zh) | 一种治疗心绞痛的中药口腔崩解片及其制备方法 | |
CN1251693C (zh) | 一种中西药复方制剂及其制备方法 | |
CN1319521C (zh) | 一种治疗心脑血管疾病的复方丹参颗粒 | |
CN1319519C (zh) | 一种治疗心脑血管疾病的复方丹参喷雾剂 | |
CN1309397C (zh) | 一种治疗心脑血管疾病的复方丹参胶囊及其制备方法 | |
CN1225270C (zh) | 一种治疗动脉粥样硬化的药物及其制备方法 | |
CN1422664A (zh) | 一种治疗心脑血管疾病的复方丹参制剂及其制备方法 | |
CN1679871A (zh) | 一种复方丹参滴丸质量控制方法 | |
CN1872230A (zh) | 一种治疗冠心病心绞痛的药物及其制备方法 | |
CN1616021A (zh) | 一种用于治疗冠心病的中药滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090114 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Li Xu Document name: Notice of Termination of Patent Rights |